52 related articles for article (PubMed ID: 19716382)
1. LIGHT protein suppresses tumor growth by augmentation of immune response.
Morishige T; Yoshioka Y; Inakura H; Tanabe A; Watanabe H; Yao X; Tsunoda S; Tsutsumi Y; Mukai Y; Okada N; Nakagawa S
Immunol Lett; 2009 Dec; 127(1):33-8. PubMed ID: 19716382
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the anti-tumor activity of native, secreted, and membrane-bound LIGHT in mouse tumor models.
Morishige T; Yoshioka Y; Tanabe A; Yao X; Mizuguchi H; Tsunoda S; Tsutsumi Y; Mukai Y; Okada N; Nakagawa S
Int Immunopharmacol; 2010 Jan; 10(1):26-33. PubMed ID: 19800994
[TBL] [Abstract][Full Text] [Related]
3. Allogeneic GM-CSF-secreting tumor cell immunotherapies generate potent anti-tumor responses comparable to autologous tumor cell immunotherapies.
Li B; Simmons A; Du T; Lin C; Moskalenko M; Gonzalez-Edick M; VanRoey M; Jooss K
Clin Immunol; 2009 Nov; 133(2):184-97. PubMed ID: 19664962
[TBL] [Abstract][Full Text] [Related]
4. Induction of potent anti-tumor immunity by direct injection of Ad-LIGHT at the site of tumor inoculation.
Zhang J; Wang Q; Zhao D; Cao X
Cytotherapy; 2007; 9(4):386-96. PubMed ID: 17573614
[TBL] [Abstract][Full Text] [Related]
5. Generation of chimeric HBc proteins with epitopes in E.coli: formation of virus-like particles and a potent inducer of antigen-specific cytotoxic immune response and anti-tumor effect in vivo.
Zhang Y; Song S; Liu C; Wang Y; Xian X; He Y; Wang J; Liu F; Sun S
Cell Immunol; 2007 May; 247(1):18-27. PubMed ID: 17707782
[TBL] [Abstract][Full Text] [Related]
6. Isolation based on L-selectin expression of immune effector T cells derived from tumor-draining lymph nodes.
Kagamu H; Touhalisky JE; Plautz GE; Krauss JC; Shu S
Cancer Res; 1996 Oct; 56(19):4338-42. PubMed ID: 8813119
[TBL] [Abstract][Full Text] [Related]
7. Anti-tumoral effect of active immunotherapy in C57BL/6 mice using a recombinant human VEGF protein as antigen and three chemically unrelated adjuvants.
Morera Y; Bequet-Romero M; Ayala M; Lamdán H; Agger EM; Andersen P; Gavilondo JV
Angiogenesis; 2008; 11(4):381-93. PubMed ID: 19034678
[TBL] [Abstract][Full Text] [Related]
8. Expression of heat-stable antigen on tumor cells provides co-stimulation for tumor-specific T cell proliferation and cytotoxicity in mice.
Wang YC; Zhu L; McHugh R; Sell KW; Selvaraj P
Eur J Immunol; 1995 May; 25(5):1163-7. PubMed ID: 7774619
[TBL] [Abstract][Full Text] [Related]
9. Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control.
Sorensen MR; Holst PJ; Pircher H; Christensen JP; Thomsen AR
Eur J Immunol; 2009 Oct; 39(10):2725-36. PubMed ID: 19637230
[TBL] [Abstract][Full Text] [Related]
10. Tumor immunotherapy targeting fibroblast activation protein, a product expressed in tumor-associated fibroblasts.
Lee J; Fassnacht M; Nair S; Boczkowski D; Gilboa E
Cancer Res; 2005 Dec; 65(23):11156-63. PubMed ID: 16322266
[TBL] [Abstract][Full Text] [Related]
11. Adeno-associated virus-mediated local delivery of LIGHT suppresses tumorigenesis in a murine cervical cancer model.
Maitituoheti M; Li Y; Wang W; Wang W; Han L; Yang R; Wang T; Wu Z; Ma D; Wang S
J Immunother; 2011 Oct; 34(8):581-7. PubMed ID: 21904218
[TBL] [Abstract][Full Text] [Related]
12. Recombinant interleukin 12 enhances cellular immune responses to vaccination only after a period of suppression.
Kurzawa H; Wysocka M; Aruga E; Chang AE; Trinchieri G; Lee WM
Cancer Res; 1998 Feb; 58(3):491-9. PubMed ID: 9458095
[TBL] [Abstract][Full Text] [Related]
13. Successful adoptive immunotherapy of murine poorly immunogenic tumor with specific effector cells generated from gene-modified tumor-primed lymph node cells.
Tanaka H; Yoshizawa H; Yamaguchi Y; Ito K; Kagamu H; Suzuki E; Gejyo F; Hamada H; Arakawa M
J Immunol; 1999 Mar; 162(6):3574-82. PubMed ID: 10092816
[TBL] [Abstract][Full Text] [Related]
14. Vascular endothelial growth factor blockade reduces intratumoral regulatory T cells and enhances the efficacy of a GM-CSF-secreting cancer immunotherapy.
Li B; Lalani AS; Harding TC; Luan B; Koprivnikar K; Huan Tu G; Prell R; VanRoey MJ; Simmons AD; Jooss K
Clin Cancer Res; 2006 Nov; 12(22):6808-16. PubMed ID: 17121902
[TBL] [Abstract][Full Text] [Related]
15. [Xenogeneic melanoma-related antigen elicits anti-tumor immune response, companied by autoimmune injury].
Tan XH; Wan YH
Zhonghua Yi Xue Za Zhi; 2005 Jun; 85(23):1596-600. PubMed ID: 16185524
[TBL] [Abstract][Full Text] [Related]
16. Attenuation of graft arterial disease by manipulation of the LIGHT pathway.
Kosuge H; Suzuki J; Kakuta T; Haraguchi G; Koga N; Futamatsu H; Gotoh R; Inobe M; Isobe M; Uede T
Arterioscler Thromb Vasc Biol; 2004 Aug; 24(8):1409-15. PubMed ID: 15178556
[TBL] [Abstract][Full Text] [Related]
17. Inducing oral immune regulation of hepatitis B virus envelope proteins suppresses the growth of hepatocellular carcinoma in mice.
Gotsman I; Alper R; Klein A; Rabbani E; Engelhardt D; Ilan Y
Cancer; 2002 Jan; 94(2):406-14. PubMed ID: 11900226
[TBL] [Abstract][Full Text] [Related]
18. Bacteriophages support anti-tumor response initiated by DC-based vaccine against murine transplantable colon carcinoma.
Pajtasz-Piasecka E; Rossowska J; Duś D; Weber-Dabrowska B; Zabłocka A; Górski A
Immunol Lett; 2008 Feb; 116(1):24-32. PubMed ID: 18166233
[TBL] [Abstract][Full Text] [Related]
19. Dendritic cell-based genetic immunization in mice with a recombinant adenovirus encoding murine TRP2 induces effective anti-melanoma immunity.
Tüting T; Steitz J; Brück J; Gambotto A; Steinbrink K; DeLeo AB; Robbins P; Knop J; Enk AH
J Gene Med; 1999; 1(6):400-6. PubMed ID: 10753065
[TBL] [Abstract][Full Text] [Related]
20. Cross-priming of T cells to intracranial tumor antigens elicits an immune response that fails in the effector phase but can be augmented with local immunotherapy.
Velicu S; Han Y; Ulasov I; Brown IE; El Andaloussi A; Gajewski TF; Lesniak MS
J Neuroimmunol; 2006 May; 174(1-2):74-81. PubMed ID: 16504307
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
